Patents by Inventor De-chu Tang

De-chu Tang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190046630
    Abstract: The present invention relates to the decontamination of anthrax spores, prophylaxis and treatment of anthrax infections and, more particularly, to compounds that act as specific inhibitors of B. anthracis germination/outgrowth-associated proteins, methods and means for making such inhibitors and their use as pharmaceuticals and/or vaccines. The invention also relates to the prophylaxis and treatment of anthrax infections and, more particularly, to vaccines and compositions that comprise B. anthracis antigens, epitopes, proteins, or nucleic acid molecules, including anthrax protective antigen, anthrax lethal factor, anthrax edema factor and anthrax proteins associated with spore germination and outgrowth, as well as methods and means for making such compositions and their use pharmaceuticals and/or vaccines.
    Type: Application
    Filed: May 14, 2018
    Publication date: February 14, 2019
    Inventors: Chun-Ming Huang, JianFeng Zhang, De-Chu Tang
  • Patent number: 9968667
    Abstract: The present invention relates to the decontamination of anthrax spores, prophylaxis and treatment of anthrax infections and, more particularly, to compounds that act as specific inhibitors of B. anthracis germination/outgrowth-associated proteins, methods and means for making such inhibitors and their use as pharmaceuticals and/or vaccines. The invention also relates to the prophylaxis and treatment of anthrax infections and, more particularly, to vaccines and compositions that comprise B. anthracis antigens, epitopes, proteins, or nucleic acid molecules, including anthrax protective antigen, anthrax lethal factor, anthrax edema factor and anthrax proteins associated with spore germination and outgrowth, as well as methods and means for making such compositions and their use pharmaceuticals and/or vaccines.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: May 15, 2018
    Assignee: Altimmune Inc.
    Inventors: Chun-Ming Huang, JianFeng Zhang, De-Chu Tang
  • Publication number: 20160114020
    Abstract: The present invention relates to the decontamination of anthrax spores, prophylaxis and treatment of anthrax infections and, more particularly, to compounds that act as specific inhibitors of B. anthracis germination/outgrowth-associated proteins, methods and means for making such inhibitors and their use as pharmaceuticals and/or vaccines. The invention also relates to the prophylaxis and treatment of anthrax infections and, more particularly, to vaccines and compositions that comprise B. anthracis antigens, epitopes, proteins, or nucleic acid molecules, including anthrax protective antigen, anthrax lethal factor, anthrax edema factor and anthrax proteins associated with spore germination and outgrowth, as well as methods and means for making such compositions and their use pharmaceuticals and/or vaccines.
    Type: Application
    Filed: September 30, 2015
    Publication date: April 28, 2016
    Inventors: Chun-Ming Huang, JianFeng Zhang, De-Chu Tang
  • Publication number: 20150071964
    Abstract: Methods and compositions are provided herein for non-invasive administration of an adenoviral vector (Ad-vector) vaccine with an adjuvant, such as a TLR3 agonist. These methods provide, for example, an increase in the immune response to the vaccine, an increase in the immunogenicity of the Ad-vector vaccine, an antigen sparing effect and improved safety with an effective protective immune response to the vaccine.
    Type: Application
    Filed: September 5, 2014
    Publication date: March 12, 2015
    Applicant: VAXIN INC.
    Inventor: De-Chu Tang
  • Publication number: 20070178115
    Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to recombinant human adenovirus vectors for delivery of avian immunogens and antigens, such as avian influenza into avians. The invention also provides methods of introducing and expressing an avian immunogen in avian subjects, including avian embryos, as well as methods of eliciting an immunogenic response in avian subjects to avian immunogens.
    Type: Application
    Filed: August 15, 2006
    Publication date: August 2, 2007
    Inventors: De-chu Tang, Kent Kampen, Haroldo Toro
  • Publication number: 20060233761
    Abstract: Described herein are methods for the noninvasive immunization of a subject that involve alkyl glycosides. Also described herein are compositions, kits, and devices for the noninvasive immunization of a subject.
    Type: Application
    Filed: February 23, 2006
    Publication date: October 19, 2006
    Inventors: John Arnold, Chun-Ming Huang, Elias Meezan, Dennis Pillion, De-Chu Tang
  • Publication number: 20050271689
    Abstract: The present invention relates to the decontamination of anthrax spores, prophylaxis and treatment of anthrax infections and, more particularly, to compounds that act as specific inhibitors of B. anthracis germination/outgrowth-associated proteins, methods and means for making such inhibitors and their use as pharmaceuticals and/or vaccines. The invention also relates to the prophylaxis and treatment of anthrax infections and, more particularly, to vaccines and compositions that comprise B. anthracis antigens, epitopes, proteins, or nucleic acid molecules, including anthrax protective antigen, anthrax lethal factor, anthrax edema factor and anthrax proteins associated with spore germination and outgrowth, as well as methods and means for making such compositions and their use pharmaceuticals and/or vaccines.
    Type: Application
    Filed: July 12, 2004
    Publication date: December 8, 2005
    Inventors: Chun-Ming Huang, JianFeng Zhang, De-Chu Tang
  • Publication number: 20050239701
    Abstract: The invention provides an immunogenic composition comprising a GnRH multimer and an antigenic carrier, an immunogenic composition comprising a recombinant vector containing a nucleic acid molecule encoding a GnRH multimer and optionally an antigenic carrier, antibodies elicited by the immunogenic compositions, and methods of using the immunogenic compositions and antibodies for modifying sexual physiology and behavior, improving the organoleptic properties of meat, and treating androgen-dependent prostate tumors and GnRH-sensitive ovarian tumors.
    Type: Application
    Filed: October 15, 2004
    Publication date: October 27, 2005
    Inventors: Henry Baker, De-chu Tang, Kent Van Kampen
  • Patent number: 6706693
    Abstract: The present invention provides a method of inducing an immune response in a non-invasive mode, comprising the step of: contacting skin of an individual in need of such treatment topically by applying to said skin an immunologically effective concentration of a genetic vector encoding a gene of interest. Also provided is a method of inducing an anti-tumor immune response in an animal in need of such treatment, comprising the step of: contacting skin of said animal topically by applying to said skin an immunologically effective concentration of a vector encoding a gene which encodes an antigen which induces an anti-tumor effect in said animal following administration. The genetic vector may include adenovirus recombinants, DNA/adenovirus complexes, DNA/liposome complexes, or any other vectors capable of expressing transgenes. Topical application of geneticvectors may preferably include a device as designed therein.
    Type: Grant
    Filed: January 3, 2000
    Date of Patent: March 16, 2004
    Assignee: The UAB Research Foundation
    Inventors: De-chu Tang, Donald H. Marks, David T. Curiel, Zhongkai Shi